New York S06925 mandates insurance companies and medical assistance programs to cover FDA-approved antiviral therapeutics for COVID-19 at no cost to.

New York S06925 amends the insurance law to require insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations, and medical assistance programs to cover antiviral therapeutics approved or granted emergency use authorization by the FDA for treating COVID-19. This coverage must be provided at no cost to the patient, with no annual deductibles or coinsurance.

New York S06925 mandates insurance companies and medical assistance programs to cover FDA-approved antiviral therapeutics for COVID-19 at no cost to.

New York S06925 amends the insurance law to require insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations, and medical assistance programs to cover antiviral therapeutics approved or granted emergency use authorization by the FDA for treating COVID-19. This coverage must be provided at no cost to the patient, with no annual deductibles or coinsurance.